The "CBD Massage Oil" Global Compliance Map: Regulatory Status and Formulation Advice for EU/US/Asia/Middle East
Updated: Sep 17
I. A Category Where Market Opportunity and Compliance Minefields Coexist
When a product's name contains both "CBD" and "Massage Oil," it almost represents the most high-potential yet regulation-prone intersection in the current global skincare market.
In 2026, the global CBD massage oil market reached $648.5 million and is projected to grow to $1.065 billion by 2035, at a CAGR of 5.9%. The broader context is that the global CBD skincare market was valued at $2.486 billion in 2024 and is expected to grow at a 21.4% CAGR to reach $7.835 billion by 2030.
However, at every intersection of this high-speed growth track, regulatory barriers of different countries and regions are set. The same CBD massage oil that is legally sold in Germany is a prohibited item in China, and in Dubai, it could trigger criminal prosecution.
For brand owners and OEM/ODM factories, understanding the "Global Compliance Map for CBD Massage Oils" is the most important strategic preparation before entering this category.
II. EU: Latest Scientific Opinions Released, Cosmetic Pathway Clearest
Overall Status: Topical Cosmetic Pathway Viable, Ingestible Products Remain in a Legal Gray Area
The latest development in EU CBD cosmetic regulation occurred in late 2025.
On October 30, 2025, the European Commission's Scientific Committee on Consumer Safety (SCCS) formally adopted its preliminary opinion on the use of CBD in cosmetics (SCCS/1685/25): Based on existing data, the SCCS considers the safe upper limit for CBD use in dermal and oral cosmetics to be 0.19%; for THC as an impurity, the safe upper limit in dermal and oral cosmetics is 0.00025% (2.5 ppm).
This is the most authoritative quantitative safety opinion on CBD cosmetics at the EU level to date, providing brand owners with a clear formulation concentration reference anchor.
Topical cosmetics fall under the regulatory scope of the EU Cosmetics Regulation (EC) No 1223/2009 and do not require Novel Food authorization, but they must meet safety assessment (CPSR) requirements, correct labeling, and registration in the EU Cosmetic Ingredient Database (CosIng).
Since February 2021, the European Commission has officially listed botanically derived CBD in the CosIng database, confirming that naturally extracted, THC-free CBD with appropriate source control can be safely included in topical cosmetic formulations.
Member State Differences Cannot Be Ignored:
The overall EU regulatory framework exhibits significant fragmentation: markets like Switzerland, Austria, and the Czech Republic provide more relaxed local systems for CBD cosmetics; while Italy, Ireland, and Finland continue to enforce strict measures restricting or banning CBD products containing any trace of THC.
Germany's Latest Developments (2026):
The German Federal Office of Consumer Protection and Food Safety (BVL) released updated guidelines in late 2025, clearly distinguishing between CBD health products and recreational cannabis products—a valuable compliance clarification for importers. Topical CBD products entering the German market must comply with EU Cosmetics Regulation EC 1223/2009, while meeting labeling, safety, and ingredient documentation requirements.
⚠️ Claim Red Line: Across the entire EU market, CBD cosmetics are strictly prohibited from making any therapeutic claims. Expressions like "pain relief," "treating inflammation," or "improving skin diseases" belong to the medical product domain. Cosmetics using such claims will be mandatorily classified and regulated as drugs.
III. US: 2025 Legislative Shockwaves, Topical Cosmetic Pathway Relatively Stable
Overall Status: Topical Risks Relatively Controllable, But Federal Regulations Remain in Turmoil
US CBD regulations underwent the most massive legislative adjustment since the 2018 Farm Bill in November 2025:
On November 12, 2025, Congress passed Section 781 of the Continuing Appropriations Act (H.R. 5371), making a major revision to the federal definition of "industrial hemp": The THC limit for hemp products was expanded from solely the Delta-9 THC standard to a Total THC standard (covering THCA and other THC isomers); more critically, the total THC content per container for final hemp products intended for human or animal use (including ingestion, inhalation, or topical application) must not exceed 0.4 milligrams. This clause will take effect on November 12, 2026, at which point many full-spectrum CBD products will be reclassified as controlled substances.
What Does This Change Mean for CBD Massage Oils?
The topical cosmetic pathway remains a relatively stable option: CBD massage oils and other topical products must comply with the comprehensive requirements of MoCRA (Modernization of Cosmetics Regulation Act of 2022), including: facility registration (initial and biennial renewal), product listing (product identity, label images, ingredient list, etc.), adequate safety substantiation, and the 15-day reporting obligation for serious adverse events. CBD itself does not automatically constitute a drug ingredient under the MoCRA framework—but the claims on the product determine its regulatory category: Cosmetic claims (e.g., "moisturizes skin," "soothes dryness") are subject to MoCRA; therapeutic claims (e.g., "relieves joint pain," "anti-inflammatory pain relief") will trigger FDA drug regulatory procedures.
Core Recommendation: For CBD massage oils targeting the US market, firmly maintain the "cosmetic" product positioning, use Broad Spectrum or CBD Isolate formulations, fully fulfill MoCRA registration and listing obligations, and confirm that the total THC content per container complies with the 0.4 mg limit before November 2026.
IV. Mainland China: Explicitly Prohibited, No Formulation Space
Overall Status: CBD Completely Banned in Cosmetics, Enforcement Continues to Tighten
As of 2025, China's National Medical Products Administration (NMPA) continues to enforce a strict ban on the use of cannabidiol (CBD) and all cannabis-derived ingredients in cosmetics. 2025 marks a new phase of stricter enforcement by the NMPA through digital monitoring and expanded laboratory testing: regulatory authorities conduct routine testing for prohibited ingredients in imported and cross-border e-commerce products, implement public blacklists and market announcements for non-compliant products, and the NMPA's updated testing protocol officially takes effect in March 2026.
For brand owners intending to enter the Chinese market: Any product containing CBD, industrial hemp extracts, or any part of the cannabis plant has no compliance pathway and no exemption channels in the Chinese market. This is not a matter of "needing extra applications," but a principled ban. Products developed for the Chinese market must completely exclude all cannabis-related source ingredients at the formulation stage.
V. Asia-Pacific Region: Huge Regulatory Gaps Between Countries, Case-by-Case Analysis Essential
Japan: Allowed after reform, but zero THC detection is the red line. Japan completed cannabis-related legal reforms in 2023, allowing the compliant circulation of CBD products with a THC content of 0% (detectable limit). This means products containing any detectable trace of THC are illegal; even micro-amounts constitute a violation, posing high risks for full-spectrum CBD products entering the Japanese market.
South Korea: Limited to medical use only, no compliance pathway for consumer goods. As of 2026, South Korea's CBD compliance pathway is only open for medical-use products, with THC requirements approaching zero detection. There is no legal authorization channel for CBD products in the consumer goods sector.
Hong Kong: Completely banned since 2023. Since February 2023, Hong Kong has banned the production, supply, sale, import/export, and possession of CBD products. CBD is listed as a "dangerous drug," and CBD-containing products, including cosmetics and food, are all prohibited.
Thailand: Local production allowed, imports banned. Thailand allows local cosmetic manufacturers to use four types of cannabis and industrial hemp ingredients for production but prohibits the import of cosmetic products containing these ingredients. This means cooperating with local OEM/ODM factories in Thailand is a viable pathway, but finished products cannot be exported from other countries to Thailand.
Australia: Explicitly banned for use in cosmetics. Both CBD and THC are completely banned for use in cosmetics in Australia, with no exemption pathways.
VI. Middle East Region: Comprehensive Ban, High-Risk Market
Overall Status: GCC countries like Saudi Arabia, UAE, and Qatar implement total bans; violators face criminal prosecution
Saudi Arabia's drug laws have no industrial hemp exemption clauses; carrying any CBD-containing product into the country is illegal and carries criminal legal liability. The UAE comprehensively bans all cannabis derivatives, including industrially sourced CBD, under Federal Law No. 14 of 1995; Dubai has prosecuted multiple cases against tourists and business travelers, making the criminal risk a real reality, not a theoretical warning. Qatar also bans all forms of cannabis and does not recognize industrial hemp or CBD exemptions.
As of 2026, there is no viable consumer-grade CBD export market in the Gulf Cooperation Council (GCC) region. Neither Saudi Arabia nor the UAE has an import authorization framework for consumer CBD products. Brand owners should continuously monitor regulatory dynamics, but currently, this market is completely closed to CBD massage oils.
Are you looking for a reliable Skincare factory?
A specification that passes on the bench and drifts at scale is a process-control problem, not a formula problem. We treat this as an engineering parameter with a measured control window, not a QA checkbox.
Our lines pair in-process measurement with batch-level documentation, so what is approved in the sample is what ships in the order — reorder after reorder.
By collaborating with Explore our skincare manufacturing capabilities you gain access to industry-leading expertise and innovative formulations that set your brand apart in the competitive global market. Send us your current spec and observed deviation — we will tell you whether it is a formulation fix or a process fix.
IX. The Core Value of OEM/ODM Factories in CBD Compliant Product Development
For brand owners wanting to enter the CBD massage oil track, choosing an OEM/ODM partner with cross-market compliance capabilities means:
Traceability and Document Management at the Raw Material Level: CBD raw materials must possess complete proof of origin, third-party testing COAs (including potency, pesticide residues, heavy metals, solvent residues), and precise quantitative reports of THC content.
Regulatory Pre-Validation in Formulation Design: The factory should be able to complete regulatory feasibility screening at the formulation stage based on the target sales market, avoiding compliance risks regarding CBD concentration and THC residue.
Complete Establishment of the Document System: EU CPSR (Cosmetic Product Safety Report), US MoCRA product listing, FDA facility registration—factories with global service capabilities should be able to assist or guide brand owners in building the pre-launch document system.
Deva Skincare has accumulated extensive experience in the formulation development of CBD and cannabis-related skincare products, is familiar with the regulatory frameworks of the EU, US MoCRA, Southeast Asia, and the Chinese market, and can provide brand owners with one-stop support from raw material screening and formulation design to document filing. If you are planning the development of CBD massage oils or CBD-free alternative formulations, please feel free to connect deeply with our compliance and R&D teams.
Comments